Pneumococcal conjugate vaccines for adults: Reasons for optimism and for caution

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1334-1336

  Weinberger, Daniel M ^a   Shapiro, Eugene D ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Conjugate vaccines; Pneumococcus; Pneumonia; Prevention; Vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE; PREVENAR13; VACCINE;

ADULT; ALTERNATIVE MEDICINE; BACTERIAL TRANSMISSION; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; NOTE; PNEUMOCOCCAL INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; ANIMAL; IMMUNOLOGY; PNEUMONIA, PNEUMOCOCCAL; PROCEDURES;

ADULT; ANIMALS; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, CONJUGATE;

EID: 84901434915     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28962     Document Type: Note

References (14)

1. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55; PMID:12724480; http://dx.doi.org/10.1056/NEJMoa022678
2. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60; PMID:1944423; http://dx.doi.org/10.1056/NEJM199111213252101
3. Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, Gruber W, Siber GR, Lockhart SP. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2007; 25:6164-6; PMID:17629361; http://dx.doi.org/10.1016/j.vaccine.2007.06.004
4. Bonten M, Bolkenbaas M, Huijts S, Webber C, Gault S, Gruber W, et al. Community-acquired pneumonia immunization trial in aduilta-CAPiTA. International Symposium on Pneumococci and Pneumococccal Diseases 9. Hyderabad, India, 2014.
5. Steens A, Bergsaker MAR, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31:6232-8; PMID:24176490; http://dx.doi.org/10.1016/j. vaccine.2013.10.032
6. Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M, Dutta-Linn M, Croucher NJ, Stevenson A, Finkelstein JA. Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts. J Pediatric Infect Dis Soc 2014; 3:23-32; PMID:24567842; http://dx.doi.org/10.1093/jpids/pit057
7. Walter ND, Taylor TH Jr., Dowell SF, Mathis S, Moore MR; Active Bacterial Core Surveillance System Team. Holiday spikes in pneumococcal disease among older adults. N Engl J Med 2009; 361:2584-5; PMID:20032333; http://dx.doi.org/ 10.1056/NEJMc0904844
8. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
9. Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee. Pediatr Infect Dis J 2013; 32:604-9; PMID:23348816; http://dx.doi.org/10.1097/INF.0b013e318287fe0d
10. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR; Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013; 10:e1001517; PMID:24086113; http://dx.doi.org/10.1371/ journal.pmed.1001517
11. Fedson DS. Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al. Hum Vaccin Immunother 2013; 10:24-8; PMID:24030320
12. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12; PMID:22357831; http://dx.doi.org/10.1001/jama.2012.169
13. Pride MW, Huijts SM, Wu K, Souza V, Passador S, Tinder C, Song E, Elfassy A, McNeil L, Menton R, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol 2012; 19:1131-41; PMID:22675155; http://dx.doi.org/10.1128/CVI.00064-12
14. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378:1962-73; PMID:21492929; http://dx.doi.org/10.1016/S0140-6736(10)62225-8